Crystagen
Also known as: EDP, Glu-Asp-Pro
Crystagen is a synthetic tripeptide (Glu-Asp-Pro, EDP) short-peptide bioregulator developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as an immune-system bioregulator. The Khavinson group reports it modulates immune-cell gene expression and chromatin organization, influencing T-cell, B-cell, and thymic epithelial activity via direct peptide-DNA interaction. Evidence is confined to single-group preclinical and small clinical studies; it is not FDA-approved and lacks independent Western validation. No CAS Registry Number is listed for this peptide in major chemical databases.
Who's worth your money for Crystagen
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (61) of 1 scored sellers
$105 · 20mg · 99.2% purity
Average price
$5.25/mg
Sellers
1
45-day trend
0%
1 of 1 sellers have a current price
- 🇺🇸 Certified Peptides61
✓ verified at source · 23h ago
$5.25/mg 0% vs avg$105
20mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Crystagen
Get one email when the market actually moves — no newsletter, no noise.
About Crystagen
CAS
—
Molecular formula
C14H21N3O8
Sequence
EDP
Typical dose range
No established clinical dosing; vendor research protocols commonly cite 1-2 mg/day subcutaneous or sublingual
Half-life
Not characterized in peer-reviewed pharmacokinetic literature; short-peptide bioregulators are presumed to clear rapidly (minutes)
Common research uses
Safety notes
Not FDA-approved for human therapeutic use. A Russian/Khavinson research peptide with little independent Western safety or efficacy data; sold grey-market for research use only. Not evaluated by WADA.
Reconstitution
Reconstitute lyophilized powder with bacteriostatic water; refrigerate after reconstitution.
COAs for Crystagen
1 third-party test across 1 vendor. Each card links to the full report.
3 citations indexed for Crystagen
review · 2022
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Ultrashort peptides (USPs), consisting of 2-7 amino-acid residues, are a group of signaling molecules that regulate gene expression and protein synthesis under normal conditions in various diseases and ageing. USPs serve as a basis for the development of drugs with a targeted mechanism of action.
Study · 2021
The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity
Study · 2014
[Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process]
Vilon, Timogen, Crystagen and R-1 short peptides possess various immunoprotective effects in spleen during its ageing. Both R-1 and Vilon peptides activate T-helpers.
Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.